Scientists engineered a portable CRISPR-based assay designed to detect Mpox after the 2025 outbreak in Sierra Leone. The platform aims to improve on-the-ground diagnostics and epidemic containment by enabling faster detection outside traditional lab settings. The article frames the assay as a turning point for field testing of viral pathogens by shifting the workflow toward rapid, localized readouts. If validated broadly, this type of CRISPR diagnostic could shorten time-to-result and support faster public health decision-making. For biotech and diagnostics developers, the key next step is the extent of analytical performance—sensitivity, specificity, and robustness across sample types—and how quickly the assay can be deployed in operational environments.